- Home
- FGI vs KPRX Comparison
FGI vs KPRX Comparison
Compare FGI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- KPRX
- Stock Information
- Founded
- FGI 1987
- KPRX 1998
- Country
- FGI United States
- KPRX United States
- Employees
- FGI N/A
- KPRX N/A
- Industry
- FGI Industrial Specialties
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FGI Industrials
- KPRX Health Care
- Exchange
- FGI Nasdaq
- KPRX Nasdaq
- Market Cap
- FGI 9.4M
- KPRX 10.0M
- IPO Year
- FGI 2022
- KPRX N/A
- Fundamental
- Price
- FGI $0.80
- KPRX $3.20
- Analyst Decision
- FGI
- KPRX Strong Buy
- Analyst Count
- FGI 0
- KPRX 1
- Target Price
- FGI N/A
- KPRX $10.00
- AVG Volume (30 Days)
- FGI 10.0K
- KPRX 46.6K
- Earning Date
- FGI 11-11-2024
- KPRX 11-08-2024
- Dividend Yield
- FGI N/A
- KPRX N/A
- EPS Growth
- FGI N/A
- KPRX N/A
- EPS
- FGI N/A
- KPRX 1.69
- Revenue
- FGI $127,180,460.00
- KPRX $16,020,000.00
- Revenue This Year
- FGI $11.39
- KPRX N/A
- Revenue Next Year
- FGI $6.26
- KPRX N/A
- P/E Ratio
- FGI N/A
- KPRX $1.93
- Revenue Growth
- FGI 7.71
- KPRX N/A
- 52 Week Low
- FGI $0.70
- KPRX $3.00
- 52 Week High
- FGI $1.85
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- FGI 45.90
- KPRX 42.05
- Support Level
- FGI $0.75
- KPRX $3.08
- Resistance Level
- FGI $0.89
- KPRX $4.04
- Average True Range (ATR)
- FGI 0.05
- KPRX 0.28
- MACD
- FGI 0.00
- KPRX -0.03
- Stochastic Oscillator
- FGI 35.71
- KPRX 12.97
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. It offers sanitaryware, bath furniture, shower systems, customer kitchen cabinetry, and other accessory items. It is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. its revenue is generated by sanitaryware. Geographically it operates in the United States, Canada, Europe, Rest of the World, and the majority of its revenue comes from the United States.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.